PACLITAXEL SAFETY

IN.PACT Admiral Drug-Coated Balloon

Dedicated to transparency 

There have been concerns surrounding the safety of paclitaxel in therapies to treat peripheral artery disease (PAD). Medtronic is dedicated to data transparency and confident in the safety and effectiveness of our IN.PACT™ Admiral™ drug-coated balloon.

Dr. Dan Clair: An update on the FDA-Panel and the impact on practice

 Panel Discussion

Does Drug Dose Impact Mortality Following PAD Treatment with Paclitaxel-eluting or Coated Devices?

A Panel Discussion: Andrew Holden, M.D.; Michael R. Jaff, D.O.; Peter A. Schneider, M.D.
More information (see more)Less information (see less)

IN.PACT PATIENT-LEVEL META-ANALYSIS

DCBs Over The Long-Term: Are They Safe For Our PAD Patients?

Insights from the IN.PACT DCB Program: Peter A. Schneider, M.D.
More information (see more)Less information (see less)

To confirm the safety of our IN.PACT Admiral DCB, an independent, patient-level analysis was conducted by the Baim Institute for Clinical Research, formerly HCRI, on all subjects from all of our studies treated with IN.PACT Admiral DCB. This analysis included 1,980 patients who were enrolled across our IN.PACT clinical programs.

The results from the independent, patient-level analysis found NO correlation between paclitaxel dose and mortality.1  

  

Document thumbnail

There was NO difference in total mean dose of paclitaxel between DCB patients who survived vs. those who died.1

View Nominal Dose Data
Document thumbnail

There was no correlation between survival status of patients stratified by paclitaxel dose.1

View Dose Tercile Data
Document thumbnail

Paclitaxel was not identified as a predictor for mortality in a multivariable analysis.1 

View Multivariable Analysis

RESOURCES 

Medtronic Letter in Response to FDA Paclitaxel Letter

IN.PACT Admiral Patient-level Safety Data
Presented at Charing Cross by Dr. Schneider.

JACC Manuscript 
Mortality Not Correlated With Paclitaxel Exposure
An Independent Patient-Level Meta-Analysis of a Drug-Coated Balloon

Peter A. Schneider, John R. Laird, Gheorghe Doros, Qi Gao, Gary Ansel, Marianne Brodmann, Antonio Micari, Mehdi H. Shishehbor, Gunnar Tepe and Thomas Zeller

1

Schneider P. DCBs Over The Long-term: Are They Safe For Our PAD Patients? Insights From The IN.PACT DCB Program. Presented at Charing Cross 2019; San Francisco, CA.